Responses
Inflammatory bowel disease
Original article
Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial
Compose a Response to This Article
Other responses
No responses have been published for this article.